secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0000950170-23-005069
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Syndax Q4 2022 net loss $39.2M; revumenib topline data expected Q3 2023
-----------------------------------------------------------------------

- Net loss of $39.2M ($0.62 per share) for Q4 2022 vs net gain of $96.2M ($1.81) in Q4 2021.
- Cash and investments $481.3M as of Dec 31, 2022; raised $162M from December stock offering.
- Revumenib topline data from AUGMENT-101 KMT2Ar cohort expected Q3 2023; NDA filing by year-end 2023.
- Axatilimab topline data from pivotal AGAVE-201 expected mid-2023; BLA filing by year-end 2023.
- Guidance: Full year 2023 total operating expenses $225-240M, R&D $160-175M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000095017023005069/0000950170-23-005069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000095017023005069/sndx-20230228.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-005069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer